Abstract: The present invention aims to realize (1) manufacture of a mesoporous composite powder or thin film composed of nanocrystalline metal oxide—glass having a three-dimensional structure with a large specific surface area, (2) construction of a porous structure framework with nanocrystalline metal oxide crystal and a slight amount of glass phase (SiO2 or P2O5, B2O3), (3) control of crystal growth of metal oxide with a slight amount of glass phase (SiO2 or P2O5, B2O3), (4) simplification of the manufacturing process, and (5) use thereof in manufacture of a lithium intercalation electric device, photocatalytic device, solar battery and energy storage device. Provided are a nanocrystal oxide—glass mesoporous composite powder or thin film having a three-dimensional structure with regularly arranged mesopores, and a secondary battery comprising the same.
Type:
Grant
Filed:
November 16, 2004
Date of Patent:
August 10, 2010
Assignee:
National Institute of Advanced Industrial Science and Technology
Abstract: The present invention provides compositions, desirably pharmaceutical compositions, containing micronized tanaproget. The compositions can also contain microcrystalline cellulose, croscarmellose sodium, anhydrous lactose, magnesium stearate, micronized edetate calcium disodium hydrous, and micronized sodium thiosulfate pentahydrate. The compositions are useful in contraception and hormone replacement therapy and in the treatment and/or prevention of uterine myometrial fibroids, benign prostatic hypertrophy, benign and malignant neoplastic disease, dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, and carcinomas and adenocarcinomas of the pituitary, endometrium, kidney, ovary, breast, colon, and prostate and other hormone-dependent tumors, and in the preparation of medicaments useful therefor. Additional uses include stimulation of food intake.
Abstract: An AlRu sputtering target that is a sintered body composed of an AlRu intermetallic compound of 95 vol. % or more is provided. It is manufactured by a stable and low-cost method that provides it with an even texture, significantly reduces oxygen, prevents or suppresses the generation of particles, and improves the yield ratio of deposition goods.
Abstract: Tanaproget polymorph Form II, processes for preparing tanaproget polymorph Form II, pharmaceutical compositions including tanaproget polymorph Form II, micronized tanaproget polymorph Form II, and processes for converting Form II to tanaproget Form I are provided. Also provided are methods of contraception, hormone replacement therapy, stimulation of food intake and treating or preventing uterine myometrial fibroids, benign prostatic hypertrophy, benign and malignant neoplastic disease, dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, or carcinomas and adenocarcinomas comprising administering polymorph Form II to a mammalian subject.
Type:
Grant
Filed:
April 26, 2006
Date of Patent:
July 20, 2010
Assignee:
Wyeth LLC
Inventors:
Marc Sadler Tesconi, Mannching Sherry Ku, Yan Xu
Abstract: Processes for preparing oxindoles, which can be utilized in the preparation of a variety of useful compounds, and methods for minimizing or preventing N-alkylation of amide containing compounds, including oxindoles, are provided.
Type:
Grant
Filed:
July 27, 2006
Date of Patent:
July 13, 2010
Assignee:
Wyeth LLC
Inventors:
Yanzhong Wu, Bogdan Kazimierz Wilk, Zhixian Ding, Xinxu Shi, Charles Chao Wu, Panolil Raveendranath, Haris Durutlic
Abstract: Methods are provided for the diagnosis and treatment of patients with increased risk of preeclampsia. The methods involve measuring levels of TGF-?3, receptors of cytokines of the TG? family, or HIF-1?.
Type:
Grant
Filed:
October 16, 2008
Date of Patent:
July 13, 2010
Assignee:
Mount Sinai Hospital
Inventors:
Isabella Caniggia, Martin Post, Stephen Lye
Abstract: The present invention relates to liposome formulations that are physically stable. In particular the present invention relates to steric stabilization of cationic liposomes by incorporating glycolipids into the liposomes. The stabilized liposomes can be used either as an adjuvant for antigenic components or as a drug delivery system. In particular the invention relates to vaccines with adjuvants in aqueous media for immunization, where the final product is stable.
Type:
Grant
Filed:
July 5, 2005
Date of Patent:
July 6, 2010
Assignee:
Statens Serum Institut
Inventors:
Jesper Davidsen, Peter Andersen, Ida Rosenkrands
Abstract: Compounds of the following structure are provided, wherein n, R1-R3 and R6-R9 are defined below, as are methods of preparing and using these compounds for contraception; treating or preventing fibroids, uterine leiomyomata, endometriosis, dysfunctional bleeding, polycystic ovary syndrome, and hormone-dependent carcinomas; providing hormone replacement therapy; stimulating food intake; synchronizing estrus; and treating cycle-related symptoms.
Abstract: A bowling game kit suitable for use on a sand beach comprises a backstop and an elongated flexible rectangular sheet of material connected at one end of the backstop and having one or more target holes adjacent the backstop, which can be in register with buckets situated in depressions formed in the sand. The elongated sheet can be wrapped around the backstop, forming an elongated enclosure in which the buckets and other components can be stored and transported.
Abstract: Provided is a tantalum sputtering target having a crystal structure in which the (222) orientation is preferential from a position 10% of the target thickness toward the center face of the target, and a manufacturing method of a tantalum sputtering target, including the steps of forging and recrystallization annealing, and thereafter rolling, a tantalum ingot or billet having been subject to melting and casting, and forming a crystal structure in which the (222) orientation is preferential from a position of 10% of the target thickness toward the center face of the target. As a result, evenness (uniformity) of the film is enhanced, and quality of the sputter deposition is improved.
Abstract: Provided is iron silicide powder in which the content of oxygen as the gas component is 1500 ppm or less, and a method of manufacturing such iron silicide powder including the steps of reducing iron oxide with hydrogen to prepare iron powder, heating the iron powder and Si powder in a non-oxidizing atmosphere to prepare synthetic powder containing FeSi as its primary component, and adding and mixing Si powder once again thereto and heating this in a non-oxidizing atmosphere to prepare iron silicide powder containing FeSi2 as its primary component. The content of oxygen as the gas component contained in the iron silicide powder will decrease, and the iron silicide powder can be easily pulverized as a result thereof. Thus, the mixture of impurities when the pulverization is unsatisfactory will be reduced, the specific surface area of the iron silicide powder will increase, and the density can be enhanced upon sintering the iron silicide powder.
Abstract: Provided is a copper alloy sputtering target containing 0.01 to (less than) 0.5 wt % of at least 1 element selected from Al or Sn, and containing Mn or Si in a total amount of 0.25 wtppm or less. The above copper alloy sputtering target allows the formation of a wiring material for a semiconductor element, in particular, a seed layer being stable, uniform and free from the occurrence of coagulation during electrolytic copper plating and exhibits excellent sputtering film formation characteristics. A semiconductor element wiring formed with this target is also provided.
Abstract: A method for the diagnosis, prognosis, and monitoring of ovarian cancer in a subject by detecting hK10 in a sample from the subject, preferably a serum sample or tumor tissue extract. hK10 may be measured using a reagent that detects or binds to hK10 preferably antibodies specifically reactive with hK10 or a part thereof. Imaging methods for tumors associated with hK10 are also described using an agent that binds to hK10 which had a label for imaging the tumor.
Abstract: Provided is high purity nickel or nickel alloy target for magnetron sputtering having superior sputtering film uniformity and in which the magnetic permeability of the target is 100 or more, and this high purity nickel or a nickel alloy target for magnetron sputtering capable of achieving a favorable film uniformity (evenness of film thickness) and superior in plasma ignition (firing) even during the manufacturing process employing a 300 mm wafer. The present invention also provides the manufacturing method of such high purity nickel or nickel alloy target.
Abstract: A training device for use as a playing field obstacle during athletic training exercises. The training device includes a weighted base supportable on an underlying ground surface. The base has at least one wheel enabling ready repositioning of the base on the playing field and an upper wall with an upward-opening slot. The base can also include a dummy obstacle having a body portion and a base plug portion. The base plug portion is receivable within the slot of the base for connecting the dummy obstacle to the base such that, when the dummy obstacle is connected to the base, the body portion of the dummy obstacle is supported in a substantially upright position. The base may further include one or more coaching sticks removably secured within receptacles in a position extending or projecting from the base.
Abstract: A method of selectively preparing a chiral 2S-amino alcohol useful in preparation of an amide sulfonated or acylated with alkyl, substituted aryl or substituted heteroaryl is described. The method involves reacting a di-tert-butyl diazene-1,2-dicarboxylate with a (4S)-4-benzyl-3-[(S)-trifluoromethyl-alkyl substituted alkanoyl]-1,3-oxazolidin-2-one to afford a di-tert-butyl 1-(1S,2S)-([(4S)-4-benzyl-2-oxo-1,3-oxazolidine-3-yl]-carbonyl}-trifluoromethyl-alkyl substituted alkyl)hydrazine-1,2-dicarboxylate. This dicarboxylate is then reduced to yield di-tert-butyl 1-(1S,2S)-[trifluoromethyl-alkyl substituted alkyl]hydrazine-1-(hydroxymethyl)-1,2-dicarboxylate. The resulting product is deblocked with an acid to yield the acid addition salt of (2S,3S)-trifluoro-hydrazino-methyl alkan-1-ol. The acid addition salt of (2S,3S)-trifluoro-2-hydrazino-methyl alkan-1-ol is hydrogenated in the presence of a suitable metal catalyst to yield the amino alcohol (2S,3S)-2-amino-trifluoro-methyl alkan-1-ol HCl.
Type:
Grant
Filed:
August 24, 2009
Date of Patent:
June 15, 2010
Assignee:
Wyeth LLC
Inventors:
John Sellstedt, Gloria Cheal, Razzak Noureldin, Anita Wai-Yin Chan, Panolil Raveendranath, Thomas Joseph Caggiano
Abstract: A method of removing an organic, preferably polymeric, light-emitting material (4) from defined areas of a substrate (1) comprises the steps of arranging a shadow mask (5) to overlie the organic material other than in the defined areas, and applying a beam of ions (7) to the defined areas through the mask. The method is useful in forming organic light-emitting diode arrays.
Type:
Grant
Filed:
April 2, 2004
Date of Patent:
June 8, 2010
Assignee:
Microemissive Displays Limited
Inventors:
Alastair Robert Buckley, Georg Karl Herman Bodammer, Carsten Giebeler
Abstract: An iron-based sintered body with a rustproof function comprises a layer containing 0.01 to 5 at % of indium on the surface of the iron-based sintered body, or an iron-based sintered body with a rustproof function contains 0.01 to 5 at % of indium throughout the sintered body, and the iron-based sintered body having iron as its principal component is manufactured by performing sintering in a gas atmosphere containing indium vapor or indium. Thereby obtained is an iron-based sintered body, as well as the manufacturing method thereof, capable of easily improving the rustproof effect without having to hardly change the conventional process.
Abstract: In one embodiment, compounds of the following structure are described, wherein R1to R7are described herein. Also provided are methods for preparing these compounds and methods of contraception; treating or preventing fibroids; treating or preventing uterine leiomyomata; treating or preventing endometriosis, dysfunctional bleeding, and polycystic ovary syndrome; treating or preventing hormone-dependent carcinomas; providing hormone replacement therapy; stimulating food intake; synchronizing estrus; and treating cycle-related symptoms using the compounds described herein.
Type:
Grant
Filed:
March 4, 2008
Date of Patent:
May 25, 2010
Assignee:
Wyeth LLC
Inventors:
Casey Cameron McComas, Andrew Fensome, Michael Anthony Marella